Tier 2 — strong

Calcium alpha-ketoglutarate administration to malnourished hemodialysis patients improves plasma arginine concentrations

Riedel E, Hampl H, Steudle V, Nündel M
Mineral and Electrolyte Metabolism 1996 22(1-3):119-122

Bibliography

PubMed
PMID 8676801
Funding
Funding information is not available in the PubMed record reviewed for this entry.
Competing interests
Competing-interest information is not reported in the PubMed record reviewed for this entry.

Study snapshot

DesignOne-year clinical intervention in malnourished hemodialysis patients.
ModelAdults receiving maintenance hemodialysis with malnutrition.
Sample24 patients.
InterventionOral calcium alpha-ketoglutarate; dose is not stated in the PubMed abstract.
Duration1 year.
EndpointsPlasma arginine; Proline; Histidine; Serum phosphate; Urea

What the study showed, in plain terms

This clinical study followed 24 malnourished hemodialysis patients receiving Ca-AKG for one year.

Plasma arginine increased, while phosphate and urea fell over the observation period. The study therefore contributes unusually long-duration human exposure data for Ca-AKG.

Because the participants had chronic kidney failure and were using Ca-AKG in a renal/nutritional context, the results cannot be treated as healthy-aging efficacy evidence.

Key findings

  • One year of Ca-AKG exposure was associated with a significant increase in plasma arginine.
  • Plasma proline and histidine also increased.
  • Serum phosphate and urea decreased during treatment.

What this study can and cannot tell us

  • No placebo-controlled healthy population.
  • The dialysis population has altered mineral and amino-acid metabolism.
  • The PubMed abstract does not provide a clear dose, so this study should not be used to define a supplement dose.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified